Cancer Vaccine Shows Promise
A vaccine designed to combat a variety of cancers has produced positive results in early laboratory testing on human cells and humanized mice, according to IFLScience.com. The vaccine, developed by the Translational Research Institute in Australia in collaboration with the University of Queensland has produced promising results in the immune system recognizing and attacking certain tumors, which may have huge implications for the development of a large-scale cancer vaccine.
“We are hoping this vaccine could be used to treat blood cancers, (myeloid leukemia, non-Hodgkin’s lymphoma, multiple myeloma, and pediatric leukemias) plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma,” lead researcher Associate Professor Kristen Radford said in a press release. “Our new vaccine is comprised of human antibodies fused with tumor-specific protein, and we are investigating its capacity to target human cells while activating the memory of the tumor cells.”
This vaccine contains a mixture of antibodies that have been fused to tumor-specific proteins that evoke an immune response when they come into contact with a type of white blood cell known as dendritic cells.
